Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Accumulated Expenses (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Accumulated Expenses for 5 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 52.85% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, down 52.85% year-over-year, with the annual reading at $3.7 million for FY2025, 52.85% down from the prior year.
  • Accumulated Expenses hit $3.7 million in Q4 2025 for Kezar Life Sciences, down from $3.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.7 million in Q3 2023 to a low of $849000.0 in Q1 2021.
  • Historically, Accumulated Expenses has averaged $5.2 million across 5 years, with a median of $5.3 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: soared 543.59% in 2023 and later crashed 59.36% in 2025.
  • Year by year, Accumulated Expenses stood at $1.6 million in 2021, then tumbled by 38.67% to $1.0 million in 2022, then skyrocketed by 543.59% to $6.5 million in 2023, then rose by 22.43% to $7.9 million in 2024, then tumbled by 52.85% to $3.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for KZR at $3.7 million in Q4 2025, $3.9 million in Q3 2025, and $4.1 million in Q2 2025.